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Familial Non-Medullary Thyroid Carcinoma (fNMTC) represents 3–7% of all thyroid tumours and is associated with some of the
highest familial risks among all cancers, with an inheritance pattern compatible with an autosomal dominant model with reduced
penetrance. We previously mapped a predisposing locus, TCO (Thyroid tumour with Cell Oxyphilia) on chromosome 19p13.2, for a
particular form of thyroid tumour characterised by cells with an abnormal proliferation of mitochondria (oxyphilic or oncocytic cells).
In the present work, we report the systematic screening of 14 candidate genes mapping to the region of linkage in affected TCO
members, that led us to identify two novel variants respectively in exon 9 and exon 13 of TIMM44, a mitochondrial inner membrane
translocase for the import in the mitochondria of nuclear-encoded proteins. These variants were co-segregating with the TCO
phenotype, were not present in a large group of controls and were predicted to negatively affect the protein (exon 9 change) or the
transcript (exon 13 change). Functional analysis was performed in vitro for both changes and although no dramatic loss of function
effects were identified for the mutant alleles, subtler effects might still be present that could alter Timm44 function and thus promote
oncocytic tumour development. Thus we suggest that TIMM44 should be considered for further studies in independent samples of
affected individuals with TCO.
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Thyroid cancer represents B1% of all human malignancies, but it
is the most common endocrine malignancy and its incidence is
increasing faster than any other malignancy in women (Malchoff
and Malchoff, 2006). In addition, because thyroid nodules are
frequently found with a prevalence up to 50% in areas with iodine
deficiency, the assessment of a possible malignant nature of a
thyroid nodule represents a serious medical problem (Schmid and
Farid, 2006).
Familial Non-Medullary Thyroid Carcinoma (fNMTC) repre-
sents 3–7% of all thyroid tumours and is associated with some of
the highest familial risks among all cancers, with a risk for first-
degree relatives of 5/10-fold. Inheritance patterns indicate that
fNMTC is an autosomal dominant trait with reduced penetrance
but a multigenic inheritance could not be excluded (Lesueur et al,
1999).
A particular form of thyroid carcinoma is the oncocytic tumour,
characterised by at least 75% of mitochondria-rich, eosinophilic
cells (oxyphilic or oncocytic cells). Tumours composed of
oncocytic cells may occur at a variety of sites but are particularly
common among thyroid tumours of follicular cell derivation
(reviewed by Tallini (1998)) and can behave aggressively possibly
due to decreased competence in iodine uptake by the tumour cells
and the consequent reduced responsiveness to radioiodine
treatment (Tallini, 1998).
It can be difficult to differentiate benign from malignant
oncocytic thyroid tumours and the overall mortality/morbidity
rate of oncocytic carcinoma appears to be higher (Stojadinovic
et al, 2001; Stojadinovic et al, 2002) than that of non-oncocytic
papillary or follicular thyroid carcinomas even when the neoplasm
is encapsulated (Ghossein et al, 2006).
Thyroid oncocytic cells have been associated with mitochondrial
abnormalities, such as deficiencies in energy-related functions,
impaired protein synthesis, and loss of electron transport
components (Maximo and Sobrinho-Simoes, 2000).
Defective mitochondrial ATP synthesis has been reported
in thyroid oncocytic tumours and cell lines, suggesting that
reduced oxidative phosphorylation might induce mitochon-
drial hyperplasia and proliferation in these tumours as a
compensatory mechanism (Savagner et al, 2001a, b). We recently
identified mutations in two mitochondrial DNA-encoded
subunits resulting in severe loss of mitochondrial activity in a
cell model of thyroid oncocytic tumours (Bonora et al, 2006).
However, it is still not clear how nuclear and mitochondrial
DNA variants influence the development of thyroid oncocytic
tumours.
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Genetics of fNMTC, we previously mapped a predisposing locus,
TCO (Thyroid tumour with Cell Oxyphilia, MIM#603386) to the
19p13.2 region (Canzian et al, 1998). The advantage of having
several multigenerational pedigrees with multiple affected indivi-
duals led us to refine the TCO region on chr19 to a 1.6Mb interval
(McKay et al, 2004). We focused on this interval in order to
identify the TCO predisposing gene. Several genes involved in
mitochondrial pathways, tumour development or thyroid func-
tions mapping to this region were analysed: EDG5; MARCH2;
LASS1; CCL25; ANGPL4; TIMM44; ELAVL1; RAB11B; LASS4;
ADAMTS10; PIN1; UBL5; GRIM19; (NIS). EDG5 is involved in
ceramide regulation and apoptosis; MARCH2 is a novel mem-
brane-bound protein with a domain similar to the cytochrome c
binding domain. LASS1 and LASS4 are human homologues of the
yeast longevity assurance gene LAG1, which regulates ceramide
levels and apoptosis (Riebeling et al, 2003). RAB11B is a GTP-
binding protein involved in trafficking and fusion of vesicles from
ER to Golgi (Hales et al, 2001). ADAMTS10 codes for a member
of metalloproteinases. A role in carcinogenesis has been shown for
ADAMTS1, as its overexpression reduced both tumorigenesis and
metastasis in vivo (Kuno et al, 2004). UBL5 encodes for an
ubiquitin-like protein, involved in protein degradation through the
proteasome pathway (Friedman et al, 2001). PIN1 codes for an
essential prolyl isomerase involved in the apoptotic response
mediated by p53/p73 proteins (Mantovani et al, 2004). ELAVL1
codes for a RNA-binding factor expressed in a wide variety of cells
and involved in RNA degradation (King et al, 2000). CCL25
encodes for a chemokine molecule (Soldevila et al, 2004). ANGPL4
codes for a factor promoting angiogenesis and is overexpressed in
several tumours (Tait and Jones, 2004). ANGPL4 expression is
regulated by several factors, such as peroxysome activating protein
and hypoxia inducible factor and it is important for the regulation
of metabolic processes (Ge et al, 2004). TIMM44 codes for a
mitochondrial inner translocase, a protein involved in the
mitochondrial import of nuclear encoded proteins. The Timm44
protein is localised to the matrix and it is loosely associated to the
inner membrane. Yeast Tim44 interacts with mtHsp70 during
protein translocation across membranes (Bauer et al, 1999).
Interestingly the vertebrate homologue of mtHsp70 is GRP75, a
stress-induced protein (Schneider et al, 1994). Mitochondrial
translocases such as Tim44 are highly conserved from yeast to
human.
GRIM19 codes for an effector of apoptosis, and is also part
of the mitochondrial Complex I. As several new missense
variants in GRIM19 were identified in sporadic cases and in
two families with multiple affected individuals presenting onco-
cytic tumours (Maximo et al, 2005), this gene was screened
in a larger panel of multigenerational families such as the ones
we collected.
Sodium/iodide symporter is a specific iodide transporter in
thyroid follicular cells, which mediates iodide uptake across the
basolateral membrane (Dohan et al, 2003). Several studies have
reported alterations in NIS transcription in thyroid tumours (Saito
et al, 1998; Lazar et al, 1999). As oncocytic thyroid tumours are
often unresponsive to radioiodine therapy, one could hypothesise
the presence of variants affecting the transcription/translation or
maturation of iodide transporter in these tumours.
MATERIALS AND METHODS
Families and controls
The eight families with thyroid oncocytic tumours included in the
study were the same as described previously (McKay et al, 2004).
Healthy donors of Caucasian origin were included as controls. The
study was approved by the relevant ethical committees, according
to the rules set by the European Comunity.
Gene characterisation
Genomic structure for each gene was obtained by BLAST
comparison (http://www.ncbi. nlm.nih.gov/BLAST) of the coding
mRNAs with the genomic sequence from Ensembl genome
browser Build 36 (http://www.ensembl.org). The following mRNA
were considered as reference sequences: NM_004230 for EDG5;
NM_001005415 for MARCH2; NM_198207 for LASS1; NM_005624
for CCL25; NM_016109 for ANGPL4; NM_006351 for TIMM44;
NM_001419 for ELAVL1; NM_004218 for RAB11B; NM_024552 for
LASS4; NM_030957 for ADAMTS10; NM_006221 for PIN1;
NM_024292 for UBL5; NM_015965 for GRIM19; NM_000453 for
NIS. Exon–intron boundaries were identified and primers
designed to cover exons and regulatory splice site regions using
the program Primer3 (http://www.genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi). Promoter regions were determined
using Promoterscan (http://zeon.well.ox.ac.uk) and PromoterIn-
spector from the Genomatix package (www.genomatix.de).
Mutation screening by direct sequencing
Genomic DNA was extracted from blood as previously described
(IMGSAC, 1998). Polymerase chain reaction conditions were the
following: 40ng of genomic DNA, 1.5–3mM MgCl2, 0.2mM each
dNTP (Roche, Indianapolis, IN, USA), 0.2mM each primer, and
0.5U Taq Gold Polymerase (Applied Biosystems, Foster City, CA,
USA) in a standard KCl buffer, final volume of 25ml. For GC-rich
regions, PCR reactions were performed with the addition of 5%
DMSO and 100mM 7-deaza-20-deoxyguanosine-50-triphosphate
(Amersham Pharmacia Biotech, Little Chalfont, UK). Forty or 44
cycles depending on the primer conditions were performed with a
touch-down protocol (14 cycles of 30s at 951C, 30s at T1  0.51C/
cycle, 30s at 721C, followed by 26–30 cycles of 30s at 951C, 30s at
T2, 30s at 721C). For GC-rich regions, each PCR step (denatura-
tion, annealing, and elongation steps) was 1min. Polymerase chain
reaction conditions and primer sequences are available on request
from the authors.
Polymerase chain reaction products were purified onto Milli-
pore PCR clean-up plates, resuspended in H2O mQ, and directly
sequenced on both strands using BigDye v1.1 (Applied Bio-
systems) according to manufacturer’s instructions. Samples were
loaded on ABI3730 automated sequencing machines (Applied
Biosystems) and analysed using Chromas version 2.0.
Prediction analysis of aa substitutions
Polymorphism Phenotyping (PolyPhen) (http://tux.embl-heidelberg.
de/ramensky/polyphen.cgi) was used to predict the possible
impact of amino acid (aa) substitutions on the protein. The
program is based on sequence comparison with homologous
proteins; profile scores position-specific independent counts
(PSIC) are generated for the allelic variants and represent the
logarithmic ratio of the likelihood of a given aa occurring at a
particular site relative to the likelihood of this aa occurring at any
site (background frequency). Position-specific independent counts
score differences above 2 indicate a damaging effect; scores
between 1.5 and 2 suggest that the variant is possibly damaging,
whereas scores below 0.5 indicate that the variant is benign.
Microsatellite analysis on chromosome 19
We examined the TCO locus in the family presenting the
P308Q variant of Timm44, in the three affected sisters and the
two daughters of one of them, for whom DNA was available.
The DNA samples were genotyped as previously reported
(Canzian et al, 1998). Markers were run onto ABI3730 Genetic
Analyser and analysed with GeneMapper v3.5 (Applied
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v2.91 (Sobel and Lange, 1996).
Generation of mutated TIMM44P308Q
pcDNA3.1. plasmid containing mouse TIMM44 cDNA
(NM_011592) in frame with the V5 epitope tag was a kind gift of
Dr Matsuoka (Okayama University Graduate School of Medicine
and Dentistry, Okayama, Japan). Site-directed mutagenesis to
insert the variant corresponding to human P308Q was performed
with QuickChange XL kit (Stratagene, Amsterdam, The Netherlands)
according to manufacturer’s instruction, using primer forward
ATCCTGAGAGTGGACCAAACCTTTGACAAGGAC and reverse
GTCCTTGTCAAAGGTTTGGTCCACTCTCAGGAT. The presence
of the mutation was verified by direct sequencing.
Cell cultures
Mouse fibroblast NIH3T3, human renal HEK293 T and simian
renal COS7 cells were grown in DMEM, 10% foetal bovine serum,
2m M L-glutamine, 100Uml
 1 penicillin and 100mgml
 1 strepto-
mycin. Cultures were grown in a humidified incubator at 371C with
5% CO2.
Co-immunoprecipitation assay
HEK293 T cells (2 10
5) were transfected with 5mg pcDNA3.
1V5Tim44. Wild type (wt) and mutant, using Lipofectamine
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s
instructions. After 48h, cells were washed once in PBS and lysed in
Triton buffer (10mM TrisHCl pH 8.0, 50mM NaCl, 0.5%v/v Triton
X-100, 10mM PMSF and a cocktail of protease inhibitors, Roche)
on ice for 15min. Cells were collected and residual clots disrupted
by passing through insulin syringe. Protein concentration was
evaluated with the DC protein concentration assay
Kit (Biorad, Hercules, CA, USA). Equal amount of each lysate
was subjected to immunoprecipitation with 2mg anti-GRP75
goat antibody (Santa Cruz Biotechnology, CA, USA) for 2h at
41C in Triton buffer. Protein-G sepharose slurry (40ml) (Sigma-
Aldrich, St. Louis, MO, USA) were added to each immuno-
precipitation reaction for 16h at 41C. Immunoprecipitates were
washed twice in Triton buffer for 1min at 41C at 8000g. Proteins
were eluted by heating at 951C for 5min in Laemli buffer and
centrifugation at 8000g 1min.
Immunoprecipitates and corresponding cell lysates were
separated by SDS gel electrophoresis on a 10% polyacrylamide
gel, transferred onto nitrocellulose membrane (GEHealthcare,
Amersham Biosciences, Little Chalfont, UK) and subjected to
Western blotting with the Western Breeze kit, using mouse
monoclonal anti-V5 antibody (Invitrogen) diluted 1:5000, accord-
ing to manufacturer’s instructions.
P1 pAltermax TIMM44 exon 13-minigene generation
Polymerase chain reaction products for the genomic region
surrounding exon 13 of human TIMM44 were amplified from
genomic DNA using primer forward ATGCGAATTCTACCAAGG
CTGAGTGGTTCC, inserting an EcoRI restriction site, and primer
reverse GGACCCTGAGTTGGAAGACtctagacgta, inserting a XbaI
restriction site for cloning into the P1 pAltermax vector (a kind gift
of Dr Gareth Eldvige, Wellcome Trust Centre, Oxford, UK).
Polymerase chain reaction amplification was carried out using
160ng genomic DNA from the heterozygous carrier of exon 13
variant, using the following conditions: 2.5mM MgCl2, 0.5mM
dNTPs, 0.2mM primers, 5U Pfx High Fidelity Polymerase (Invitro-
gen) in 50ml final volume. Thirty-five cycles were performed as
follows: 951C 2min, 951C3 0 s ,5 8 1C3 0 s ,6 8 1C 1min 30s, with a
final step at 681C for 7min. Before purification, 0.5U of
TaqPolymerase were added to the PCR mixture in order to add
protruding A, for 10min at 721C. The expected 913bp long PCR
product was purified onto Millipore plate and cloned into
pcDNA2.1 vector using the TA cloning kit (Invitrogen), according
to manufacturer’s instructions. Plasmids carrying either the wt or
the mutant exon 13 variant were discriminated by direct
sequencing. Exon 13 products were recovered by purification
with Qiagen gel extraction kit of plasmid double digestion with
EcoRI-XbaI (MBI Fermentas, Hanover, MD, USA) according to
standard protocol. P1 pAltermax plasmid was double-digested
with EcoRI-XbaI (Fermentas), dephosphorylated with 10U of
Shrimp Alkaline Phosphatase (Fermentas) according to manufac-
turer’s instruction, and purified by ethanol precipitation. The PCR
products, either wt or mutant, were cloned into P1 pAltermax
vector and plasmids sequenced.
Splicing alteration analysis
COS7 cells were transfected with 5mg of the empty P1 plasmid or
with the wt or mutant exon 13 insert, using Lipofectamine as
described previously. After 48h, total RNA was extracted using
Qiagen RNeasy kit (Qiagen, GmBH, D), according to manufac-
turer’s instructions, and subjected to RNase-free DNase I digestion
(Qiagen). RNA DNase I-treated (5mg) was used for RT with
Superscript III kit (Invitrogen) in a final volume of 20ml. One out
of 10 of RT reaction was used for amplification with primer
forward specific for pAltermax vector F AAGGCTAGAGTACT
TAATACGA R and reverse specific for human TIMM44 F
CGAGAATCTGCTCGGTGCT R. Polymerase chain reaction ampli-
fication was carried out in a final volume of 25ml, 0.5U of TaqGold
Polymerase, 0.2mM dNTPs, 0.2mM primers in a standard KCl
buffer. Forty cycles were performed as follows: 951C 15min, 951C
30s 581C3 0s7 2 1C 1min. Polymerase chain reaction products were
directly sequenced as described above.
RESULTS
In order to identify the TCO predisposing gene on 19p13. 2, we
have systematically screened functional candidate genes, mapping
to the region of linkage, for the presence of aetiological mutations.
Here, we report the analysis of 14 candidate genes mapping to the
region of linkage.
Affected individuals from eight multiplex families showing
linkage to the region 19p13.2 were screened for the presence of
sequence variants in these genes. Once a variant was identified in
one affected individual, all the other family members were tested
for the presence of this change. The frequency and positions of the
changes identified throughout our screening are shown in Table 1
and Supplementary Table 1. Twenty-eight changes were identified
in the corresponding cDNA and by comparison with dbSNP
(http://www.ncbi.nlm.nih.gov/SNP/) 12 changes were considered
‘novel’. Five changes were silent substitution (G374A, and G1274A
in TIMM44, G509A and T971C in ELAVL1, C591A in LASS1), two
changes were a G-to-T substitution in the 30UTR of CCL25 (G868
T) and a C-to-T substitution in GRIM19 50UTR, one change
was a 13bp deletion in the 30UTR of MARCH2 and the others
were new missense substitutions: C925A in TIMM44 (P308Q),
G1111C (R219P) in MARCH2, A866 T (T289 M) in EDG5, T1339C
(V353A) in LASS4. The presence of all these variants was
tested in the other affected individuals of the respective families
and/or in the control group of healthy Caucasian individuals. From
this analysis, only the two variants in TIMM44, C925A, and
G1274A, appeared to co-segregate with the TCO phenotype in two
independent families and not to be present with similar
frequencies in the control group, and for this reason they were
further followed up. All the new polymorphisms have been
submitted to dbSNP.
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The new change in TIMM44 C925A maps to exon 9, and
corresponds to a nonconservative missense substitution,
P308Q, in a highly conserved position, as indicated by clustal
alignment with the orthologue proteins from different species
(Figure 1). This change was found in one family and not in 125
independent controls, and it co-segregated with the TCO
phenotype in the three affected sisters. Recruitment of other
family members led to the analysis of two daughters of one affected
member, who presented thyroid follicular adenoma but no
carcinoma with oncocytic features. They also did not carry the
change in exon 9 (data not shown). In addition, it was shown by
the analysis with nine markers on chromosome 19 short arm, that
the two daughters did not inherit the chromosome 19 risk
haplotype shared by the mother and her affected sisters (Figure 2).
An in silico analysis with PolyPhen was performed to predict the
functional role of this change. P308Q is predicted to be damaging
(PSIC score¼2.125).
In order to test the predicted potential damaging role of P308Q
change on Tim44 function, we generated a mutated mouse form,
introducing the corresponding mutated aa by site-directed
mutagenesis of pcDNA3.1 wild-type mouse Timm44 in-frame with
the C-ter V5 tag. In yeast, the interaction between Tim44 and
mtHsp70 is mediated by a specific region in Tim44 (aa 185–202),
close to the site corresponding to human missense change P308Q
(D’Silva et al, 2003, 2004). We thus hypothesised that in the
presence of the mutated aa that inserts a nonconservative
substitution from apolar to a partially charged residue, protein
binding, and interaction between Timm44 and the mammalian
homologue of mtHs70, GRP75 might be altered. In order to verify
this hypothesis, we carried out co-immunoprecipitation experi-
ments in mammalian cells transfected either with the normal or
the mutant Tim44. Experiments were repeated twice both in mouse
NIH3T3 and human HEK293 T cells with the same results in the
two cell systems: immunoprecipitation for endogenous GRP75 on
total cell lysates and Western blot analysis with antiV5- specific
antibody for recombinant Tim44 revealed that the interaction was
not abolished by the presence of the missense change in Tim44
(Figure 3 and data not shown). This result suggests that the
presence of the P308Q missense change does not affect Timm44
function.
Table 1 Changes in cDNA of TCO candidate genes on 19p13.2
PCR product Change in cDNA Type of aa change dbSNP
Het frequency in
TCO patients (%)
Het frequency in
controls (%)
TIMM44x4 G344A Silent – 12.5 NA
TIMM44x9 C925A P308Q – 12.5 0
TIMM44x13 G1274A Silent – 12.5 0
TIMM44x13 C1307T Silent rs1157923 12.5 NA
ELAVL1x3 G509A Silent – 12.5 NA
ELAVL1x5 T971C Silent – 12.5 NA
ELAVL1x5 A4024G 30UTR rs12983784 37.5 NA
CCL25x3 A303G H101R rs2032887 62.5 NA
CCL25x3 C312T T104M rs2113089 12.5 NA
CCL25x4 G379A Silent rs2303164 37.5 29.7
CCL25x5 G675A 30UTR rs2287936 25.0 NA
CCL25x5 G868T 30UTR – 12.5 NA
ADAMTS10x4 C646G T134S rs7255721 37.5 NA
ADAMTS10x26 T3548G H1101Q rs7252299 90.0 NA
ANGPTL4x7 G1362A Silent rs11672433 12.5 NA
LASS1x3 C591A Silent – 8.0 NA
LASS4x9 C997T Silent rs1127912 12.5 NA
LASS4x9 T1006C Silent rs36247 37.5 NA
LASS4x12 T1339C V353A rs17160348 12.0 NA
LASS4x12 G1376A A366T rs36259 88.0 NA
RAB11Bx5 C558T Silent rs2230876 57.0 NA
MARCH2x1 C20T 50UTR rs12150986 42.0 NA
MARCH2x2 A615G T54A rs11882865 67.0 NA
MARCH2x5 G1111C R219P rs34099346 42.9 22.5
MARCH2x5 del(CTTCCACTTCAAC)
bp1267-1280
30UTR – 13.0 3.0
GRIM19x1 C182T 50UTR – 25.0 NA
EDG5x2 A919C Silent rs2116942 14.2 NA
EDG5x2 A866T T289M – 14.2 NA
aa¼amino acid; cDNA¼complementary; NA¼not available; PCR¼polymerase chain reaction; TCO¼thyroid tumor with cell oxyphilia.
H. sapiens 302
302
303
359
309
274
276
M. musculus
R. norvegicus
G. gallus
D. melanogaster
C. elegans
S. cerevisiae
Figure 1 TIMM44 conservation through species. Alignment of Timm44 proteins in different species generated using ClustalW (www.ebi.ac.uk/clustalw):
the regions highly conserved are shown in black shades. The arrowhead shows the aa position corresponding to human P308.
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The second change G1274A co-segregating with the TCO
phenotype and not found in 125 controls maps to exon 13 and is
a silent variant. As it lies close to the 30-splice junction, we
investigated if there were putative exonic enhancer sites that might
be modified by the presence of the variant. As shown by Cartegni
et al (2006) (Liu et al, 2001), variants in the transcribed region of a
gene may affect the binding sites (exonic enhancer) of splicing
factors such as SR proteins, which promote the inclusion of that
particular exon in the transcript. Alteration of these binding sites
can induce the absence of that exon in the final messenger RNA,
with the generation of shorter transcripts and/or truncated
proteins. This phenomenon has been reported for several
disorders, such as breast cancer (Liu et al, 2001; Fackenthal
et al, 2002), spinal muscular atrophy (Cartegni et al, 2006), and
hypergammaglobulinemia (Ferrari et al, 2001).
We used the program ESEfinder v2.0 (http://rulai.cshl.edu/tools/
ESE/) to identify putative SR protein-dependent ESEs in the exon
13wt (allele G) or mutated (allele A) and to calculate the
correspondent motif scores. The A allele introduces a putative
binding site for SRp40 (score¼3.139; threshold¼2.67) and SC35
(score¼2.645; threshold¼2.383) that is absent from the G allele.
To understand if the change in exon 13 might alter the splicing
pattern of Tim44 transcript in vivo, the exon and flanking genomic
regions were amplified from the heterozygous patient and the
two allelic variants were independently cloned into a minigene
plasmid, P1 pAlterMax. This plasmid contains two synthetic exons
separated by an intronic sequence with canonical splice junctions
and with a multiple cloning where to insert the fragment with a
putative effect on splicing (Figure 4A).
COS7 cells were transfected either with each allele and with the
empty vector. Reverse transcription–polymerase chain reaction on
total RNA was performed using primers specific for the minigene
only as a control of RT, for the synthetic exon (forward primer),
and for the human Tim44 cDNA (reverse primer). Using the
couple of primers specific for both minigene and Tim44, no signal
could be detected correctly from cells transfected with the empty
vector. Cells transfected with the wt or with the mutant form
produced the same PCR product the size of which (150bp) was
Marker order
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Figure 2 Risk haplotype on chromosome 19. Pedigree and haplotype reconstruction across 19p13.2 in the family carrying the change C925A (P308Q) in
TIMM44. In bold it is shown the location of the exon 9 variants in TIMM44.
HEK293-Timm44 wt
HEK293-Timm44 P308Q
HEK293 not transfected
HEK293-Timm44 wt
HEK293-Timm44 P308Q
HEK293 not transfected
Cell lysates Co_IP
IPGRP75:    −−−
WBV5:
55 kDa
45 kDa
Lanes:
+++ + ++
+ ++
6 5 4 123
Figure 3 Co-immunoprecipitation experiments for Timm44 P308Q
variant. Western blot analysis for V5 tag specific for recombinant Timm44
of cell lysates (lanes 1–3) and immunoprecipitates (lanes 4–6) for GRP75
of HEK293T cells transfected with the plasmid carrying either the wild type
(lanes 1 and 4) or the P308Q form (lanes 2 and 5) of Timm44 and the
control HEK293 T not transfected (lanes 3 and 6).
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and TIMM44 exon (Figure 4B). Resequencing confirmed the
correct sequence of the PCR fragment (data not shown). No
difference was identified between the wt and the two allelic
variants of exon 13.
DISCUSSION
The present work reports the systematic screening of positional
and functional candidate genes predisposing to a familial form of
thyroid cancer with oxyphilic cells. Familial clustering of oncocytic
tumours has been reported and our group has previously mapped
a predisposing locus on chromosome 19p13.2, which is associated
in families with the transmission of an autosomal dominant trait
with reduced penetrance (Canzian et al, 1998; McKay et al, 2004).
It has been recently pointed out by Sobrinho-Simoes et al (2005)
that every type of thyroid neoplasm has its oncocytic counterpart;
however the complex interplay between genetic and environmental
factors that gives rise to this tumour phenotype is not clear. The
fact that oncocytic tumours can be both multiple and familial
strongly suggests that there is a germline mutation conferring an
increased liability to develop this type of thyroid tumour. The
gene, which could be referred to as TCO because it confers a
liability to oncocytic follicular cell tumour development, is likely to
be involved in at least some sporadic oncocytic tumours. In this
way, the presence of several families presenting a TCO phenotype
is of great help to identify the predisposing gene.
We therefore decided to screen for mutations candidate genes
mapping to 19p13.2 in the families contributing to linkage to the
region, with a priority for genes involved in mitochondria and/or
tumour development.
No relevant variants were identified in EDG5; MARCH2; LASS1;
CCL25; ANGPL4; ELAVL1; RAB11B; LASS4; ADAMTS10; PIN1;
UBL5; GRIM19; NIS. GRIM19 was previously analysed by another
group and some missense variants were identified in sporadic and
familial cases, but not in the original family where the locus on
chromosome 19 was identified (Maximo et al, 2005). Our negative
findings confirm the idea that this gene is not related to
predisposition to familial forms of TCO. In accordance with our
results, no mutations in NIS were identified in sporadic thyroid
tumours in previous published screenings (Russo et al, 2001).
However, these studies did not include familial forms of TCO,
which significantly contributed to the linkage on chromosome
19p13.2, where the gene maps.
Our screening identified two interesting TIMM44 variants in two
different families. These variants co-segregated with the oncocytic
carcinoma phenotype and were not present in a large number of
controls. One change was a a missense variant in exon 9 and the
second change a silent variant that inserted a putative exonic
enhancer site in exon 13. We analysed the effects on TIMM44
splicing, considering that in other forms of cancer, for example,
breast cancer owing to BRCA1 and BRCA2 mutations (Liu et al,
2001; Fackenthal et al, 2002), abnormal splicing owing to the
presence of variants altering exonic enhancer binding sites for
different SR factors can account for a significant percentage of
cases. In the present work we could not detect any splicing
alteration, ruling out a functional role for the variant in exon 13 of
TIMM44.
The analysis of the variant in exon 9, which results in the
nonconservative substitution P308Q, is more intriguing. In
general, coding SNPs that change the aa sequence and most likely
influence function are found at a lower rate and with lower
frequency than silent substitutions (Cargill et al, 1999). In the
present case, the substitution affects the, P308 human transcript
residue that is highly conserved through evolution (Figure 1), that
is predicted to be damaging, and that might affect protein
function. The presence of the same mutation on the risk haplotype
shared by all the three affected members with oncocytic thyroid
carcinoma, but not in the individuals of the same family presenting
adenoma without oncocytic features, suggests that this change
might be relevant for the development of oncocytic thyroid
carcinoma. The role of Tim44 in mitochondrial import of nuclear-
encoded proteins has been extensively studied in yeast, where it
has been shown that Tim44 is present at the inner mitochondrial
membrane on the matrix side and promotes the transfer of
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RT− RT+
100 bp
200 bp
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Figure 4 Splicing analysis for TIMM44 exon 13 variant. (A) P1 pAltermax plasmid structure, showing the two synthetic exons interrupetd by an intronic
sequence carrying the multiple cloning site. Abbreviation: P1-F and P1-R primers forward and reverse specific for the synthetic exons of the vector. In the
box it is shown the genomic sequence including exon 13 inserted in the P1 vector. In bold it is shown the change G1276A; underlined it is shown the
sequence of the reverse primer specific for human TIMM44 encompassing the TGA stop codon; underlined and hatched it is shown the sequence of primers
used for cloning, with the restriction sites shaded in grey. (B) RT–PCR results using the P1-F primer and the human primer specific for TIMM44 on the
cDNA from COS7 cells not transfected (lanes 1 and 5) transfected with the empty P1 vector (lanes 2 and 6), allele G-containing vector (lanes 3 and 7), allele
A-containing vector (lanes 4 and 8). Lanes 1–4: no superscript in the cDNA reaction mix; lanes 5–8 superscript present in the cDNA reaction mix. The
PCR products are correctly visible only in the RTþ lanes of cells transfected with the vectors carrying the two alleles (lanes 7 and 8).
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sunfolded proteins passing through the inner mitochondrial
channel formed by the integral membrane proteins Tim17 and
Tim23 by binding to mtHsp70 (D’Silva et al, 2004). MtHsp70 in
turn recruits Mseg1 and through ATP hydrolysis completes the
passage in the matrix of mitochondrial proteins (Krimmer et al,
2000).
An important role for Tim44 in regulating mitochondrial
functions has been recently shown by Matsuoka et al (2005),
who demonstrated that introducing wild type Tim44 in a mouse
model of diabetes reduced the production of reactive oxygen
species (ROS) and decreased the neointimal proliferation of
injured arteries in diabetic mice.
An excess of ROS can damage mitochondria and mtDNA,
eventually contributing to promote tumour development (Eng
et al, 2003). An enhanced ROS generation has been observed in
inherited complex I deficiencies (Pitkanen and Robinson, 1996;
Luo et al, 1997). It has been reported that transmitochondrial
cytoplasmatic hybrids or cybrids (Vergani et al, 1995) carrying the
three most common Leber’s hereditary optic neuropathy patho-
genic mutations in complex I subunit genes show a partial
respiratory defect as well as a significant increase in ROS
production (Floreani et al, 2005).
We recently detected in a cell model of oncocytic tumours an
increased production of ROS, in presence of specific disruptive
complex I and III mitochondrial DNA mutations (Bonora et al,
2006). These findings are compatible with poorly functioning or
nonfunctional mitochondria in oncocytic neoplasms. If Tim44 has
a fundamental role in protein transport and ROS production
regulation, any impairment in its functions might be related to
oncocytic proliferation.
We tested whether the binding to the human homologue of
mtHsp70 was impaired by the P308Q variants. As shown in the
results, no difference was observed suggesting that the P308Q
variant does not impair Tim44. However, we cannot rule out a
more subtle effects in protein transport, such as less effective
transfer of the proteins from the inner import channel. Further
analysis is warranted to study the role of P308Q with the
development of oncocytic alterations, possibly using Saccharo-
myces cerevisiae models where the different steps of mitochondrial
import have been defined in details (for a review see Krimmer
et al, 2000).
Association studies would greatly help understanding the role of
TIMM44 in TCO and in defining, if present, a risk haplotype for
the gene. It has been calculated that a sample size of 130–160
affected sib-pairs is needed to provide 80% power at the 10
 5
significance level to detect a locus having a genotypic risk ratio of 2
and a moderate allele frequency (P¼0.1–0.4) (Risch and
Merikangas, 1996). Nevertheless, similar sample sizes are very
difficult to achieve, given the rarity of the familial TCO phenotype.
We also tested the presence of the variants in TIMM44 in a panel of
sporadic NMTC cases, including 41 oncocytic carcinomas, but we
did not detect any variants in this set of samples (data not shown).
However, mutations in different genes encoding for mitochondrial
proteins might lead to the development of oncocytomas, in
particular preliminary data from our group suggest that mutations
in mitochondrially encoded mitochondrial proteins play a relevant
role in sporadic cases (Gasparre, in preparation). Thus, a complex
interplay between nuclear and mitochondrial genes can be
hypothesised and we suggest that replication studies with
particular attention to the presence of the variant in exon 9, in
other independent samples of families affected by TCO will greatly
help to understand the role of TIMM44 in TCO predisposition and
development.
ACKNOWLEDGEMENTS
We thank all the families who participated in the study and the
professionals who continue to make this study possible. We thank
Manuela Vargiolu for her help in some of the experiments, Simona
Ferrari and Gareth Eldvige for helpful suggestions and discussion.
This work was supported by AIRC Grant 1145 to GT. The study
was partially supported by grants from FIRB (Rome) and from the
European Commission (Project QLRT-2000-01646) to GR.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Bauer MF, Gempel K, Reichert AS, Rappold GA, Lichtner P, Gerbitz KD,
Neupert W, Brunner M, Hofmann S (1999) Genetic and structural
characterization of the human mitochondrial inner membrane translo-
case. J Mol Biol 289: 69–82
Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A,
Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G (2006) Defective
oxydative phosphorylation in thyroid oncocytic carcinoma is associated
with pathogenic mitochondrial DNA mutations affecting complexes I
and III. Cancer Res 66: 6087–6096
Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, Levillain
P, Romeo G, Bonneau D (1998) A gene predisposing to familial thyroid
tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum
Genet 63: 1743–1748
Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane
CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A,
Warrington J, Lipshutz R, Daley GQ, Lander ES (1999) Characterization
of single-nucleotide polymorphisms in coding regions of human genes.
Nat Genet 22: 231–238
Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR (2006)
Determinants of exon 7 splicing in the spinal muscular atrophy genes,
SMN1 and SMN2. Am J Hum Genet 78: 63–77
D’Silva P, Liu Q, Walter W, Craig EA (2004) Regulated interactions of
mtHsp70 with Tim44 at the translocon in the mitochondrial inner
membrane. Nat Struct Mol Biol 11: 1084–1091
D’Silva PD, Schilke B, Walter W, Andrew A, Craig EA (2003) J protein
cochaperone of the mitochondrial inner membrane required for protein
import into the mitochondrial matrix. Proc Natl Acad Sci USA 100:
13839–13844
Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS,
Carrasco N (2003) The sodium/iodide Symporter (NIS): characterization,
regulation, and medical significance. Endocr Rev 24: 48–77
Eng C, Kiuru M, Fernandez MJ, Aaltonen LA (2003) A role for
mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev
Cancer 3: 193–202
Fackenthal JD, Cartegni L, Krainer AR, Olopade OI (2002) BRCA2 T2722R
is a deleterious allele that causes exon skipping. Am J Hum Genet 71:
625–631
Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M,
Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N,
Durandy A, Tbakhi A, Notarangelo LD, Plebani A (2001) Mutations of
CD40 gene cause an autosomal recessive form of immunodeficiency with
hyper IgM. Proc Natl Acad Sci USA 98: 12614–12619
Floreani M, Napoli E, Martinuzzi A, Pantano G, De Riva V, Trevisan R,
Bisetto E, Valente L, Carelli V, Dabbeni-Sala F (2005) Antioxidant
defences in cybrids harboring mtDNA mutations associated with Leber’s
hereditary optic neuropathy. FEBS J 272: 1124–1135
Friedman JS, Koop BF, Raymond V, Walter MA (2001) Isolation of a
ubiquitin-like (UBL5) gene from a screen identifying highly expressed
and conserved iris genes. Genomics 71: 252–255
Ge H, Yang G, Yu X, Pourbahrami T, Li C (2004) Oligomerization state-
dependent hyperlipidemic effect of angiopoietin-like protein 4. J Lipid
Res 45: 2071–2079
New variants in TIMM44 in oncocytic thyroid carcinoma
E Bonora et al
1535
British Journal of Cancer (2006) 95(11), 1529–1536 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sGhossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM,
Singh B (2006) Prognostic factors of recurrence in encapsulated Hurthle
cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
Cancer 106: 1669–1676
Hales CM, Griner R, Hobdy-Henderson KC, Dorn MC, Hardy D, Kumar R,
Navarre J, Chan EK, Lapierre LA, Goldenring JR (2001) Identification
and characterization of a family of Rab11-interacting proteins. J Biol
Chem 276: 39067–39075
IMGSAC (1998) A full genome screen for autism with evidence
for linkage to a region on chromosome 7q. Hum Mol Genet 7:
571–578
King PH, Fuller JJ, Nabors LB, Detloff PJ (2000) Analysis of the 5’ end
of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory
element and evidence for conserved genomic organization. Gene 242:
125–131
Krimmer T, Rassow J, Kunau WH, Voos W, Pfanner N (2000)
Mitochondrial protein import motor: the ATPase domain of matrix
Hsp70 is crucial for binding to Tim44, while the peptide binding domain
and the carboxy-terminal segment play a stimulatory role. Mol Cell Biol
20: 5879–5887
Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K (2004) The
carboxyl-terminal half region of ADAMTS-1 suppresses both tumor-
igenicity and experimental tumor metastatic potential. Biochem Biophys
Res Commun 319: 1327–1333
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M
(1999) Expression of the Na+/I- symporter gene in human thyroid
tumors: a comparison study with other thyroid-specific genes. J Clin
Endocrinol Metab 84: 3228–3234
Lesueur F, Stark M, Tocco T, Ayadi H, Delisle MJ, Goldgar DE,
Schlumberger M, Romeo G, Canzian F (1999) Genetic heterogeneity in
familial nonmedullary thyroid carcinoma: exclusion of linkage to RET,
MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol
Metab 84: 2157–2162
Liu HX, Cartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon
skipping caused by nonsense or missense mutations in BRCA1 and other
genes. Nat Genet 27: 55–58
Luo X, Pitkanen S, kassovska-Bratinova S, Robinson BH, Lehotay DC
(1997) Excessive formation of hydroxyl radicals and ladehydic lipid
peroxidation products in cultured skin fibroblast from patients with
Complex I deifciency. J Clin Invest 99: 2877–2882
Malchoff CD, Malchoff DM (2006) Familial nonmedullary thyroid
carcinoma. Cancer Control 13: 106–110
Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R,
Blandino G, Del Sal G (2004) Pin1 links the activities of c-Abl and p300 in
regulating p73 function. Mol Cell 14: 625–636
Matsuoka T, Wada J, Hashimoto I, Zhang Y, Eguchi J, Ogawa N, Shikata K,
Kanwar YS, Makino H (2005) Gene delivery of Tim44 reduces
mitochondrial superoxide production and ameliorates neointimal
proliferation of injured carotid artery in diabetic rats. Diabetes 54:
2882–2890
Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T,
Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simoes M (2005)
Somatic and germline mutation in GRIM-19, a dual function gene
involved in mitochondrial metabolism and cell death, is linked to
mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer
92: 1892–1898
Maximo V, Sobrinho-Simoes M (2000) Hurthle cell tumours of the thyroid.
A review with emphasis on mitochondrial abnormalities with clinical
relevance. Virchows Arch 437: 107–115
McKay JD, Thompson D, Lesueur F, Stankov K, Pastore A, Watfah C, Strolz
S, Riccabona G, Moncayo R, Romeo G, Goldgar DE (2004) Evidence for
interaction between the TCO and NMTC1 loci in familial non-medullary
thyroid cancer. J Med Genet 41: 407–412
Pitkanen S, Robinson BH (1996) Mitochondrial complex I deficiency leads
to increased production of superoxide radicals and induction of
superoxide dismutase. J Clin Invest 98: 345–351
Riebeling C, Allegood JC, Wang E, Merrill AH, Jr, Futerman AH (2003) Two
mammalian longevity assurance gene (LAG1) family members, trh1 and
trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA
donors. J Biol Chem 278: 43452–43459
Risch N, Merikangas K (1996) The future of genetic studies of complex
human diseases. Science 273: 1516–1517
Russo D, Manole D, Arturi F, Suarez HG, Schlumberger M, Filetti S,
Derwahl M (2001) Absence of sodium/iodide symporter gene mutations
in differentiated human thyroid carcinomas. Thyroid 11: 37–39
Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A,
Onaya T (1998) Increased expression of the sodium/iodide symporter in
papillary thyroid carcinomas. J Clin Invest 101: 1296–1300
Savagner F, Chevrollier A, Loiseau D, Morgan C, Reynier P, Clark O,
Stepien G, Malthiery Y (2001a) Mitochondrial activity in XTC.UC1 cells
derived from thyroid oncocytoma. Thyroid 11: 327–333
Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y (2001b)
Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors.
J Clin Endocrinol Metab 86: 4920–4925
Schmid KW, Farid NR (2006) How to define follicular thyroid carcinoma?
Virchows Arch 448: 385–393
Schneider HC, Berthold J, Bauer MF, Dietmeier K, Guiard B, Brunner M,
Neupert W (1994) Mitochondrial Hsp70/MIM44 complex facilitates
protein import. Nature 371: 768–774
Sobel E, Lange K (1996) Descent graphs in pedigree analysis: applications
to haplotyping, location scores, and marker-sharing statistics. Am J Hum
Genet 58: 1323–1337
Sobrinho-Simoes M, Maximo V, Castro IV, Fonseca E, Soares P, Garcia-
Rostan G, Oliveira MC (2005) Hurthle (oncocytic) cell tumors of thyroid:
etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol 13:
29–35
Soldevila G, Licona I, Salgado A, Ramirez M, Chavez R, Garcia-Zepeda E
(2004) Impaired chemokine-induced migration during T-cell develop-
ment in the absence of Jak 3. Immunology 112: 191–200
Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP,
Brennan MF, Shaha AR, Singh B (2001) Hurthle cell carcinoma: a critical
histopathologic appraisal. J Clin Oncol 19: 2616–2625
Stojadinovic A, Hoos A, Ghossein RA, Urist MJ, Leung DH, Spiro RH,
Shah JP, Brennan MF, Singh B, Shaha AR (2002) Hurthle cell carcinoma:
a 60-year experience. Ann Surg Oncol 9(2): 197–203
Tait CR, Jones PF (2004) Angiopoietins in tumours: the angiogenic switch.
J Pathol 204: 1–10
Tallini G (1998) Oncocytic tumours. Virchows Arch 433: 5–12
Vergani L, Martinuzzi A, Carelli V, Cortelli P, Montagna P, Schievano G,
Carrozzo R, Angelini C, Lugaresi E (1995) MtDNA mutations associated
with Leber’s hereditary optic neuropathy: studies on cytoplasmic hybrid
(cybrid) cells. Biochem Biophys Res Commun 210: 880–888
New variants in TIMM44 in oncocytic thyroid carcinoma
E Bonora et al
1536
British Journal of Cancer (2006) 95(11), 1529–1536 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s